Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and diseases globally.
We are using our proprietary Sementis Copenhagen Vector (SCV) and associated manufacturing system technology for the rapid development of effective vaccines to tackle infectious diseases of highest unmet medical need as well as vaccines for pandemic preparedness.
Our lead vaccines include a combination Zika-Chikungunya vaccine (pre-Phase I clinical), a ‘second generation’ COVID-19 vaccine (pre-clinical evaluation) and a therapeutic vaccine for peanut allergy (pre-clinical evaluation).
Our vaccine technology is also under evaluation for the prevention of allergies, with potential future applications in cancer.
Sementis conducts it’s research and development activities in partnership with a team of experts in translational and clinical research at the University of South Australia, as well as through research collaborations with international companies.
The Sementis Copenhagen Vector (SCV) system is a next-generation viral-vector platform technology rationally designed to be safe, and drive highly effective humoral and cell-mediated vaccine responses to provide long lasting immune protection.
The SCV system couples a genetically engineered, non-replicative viral vector with a genetically engineered commercial manufacturing cell-line. The genes of disease antigens can be easily added to the viral vector, allowing for rapid adaptation of the vaccine against a single or multiple diseases, and then manufactured on a commercial scale.
The SCV is derived from a vaccinia virus strain that was used for the eradication of smallpox in the 1960-70s, the first ever successful disease eradication program. However, any concerns about the safety of vaccinia virus vectored vaccines have been addressed through our targeted genetic attenuation, thus making SCV vectored vaccines safe for use in humans.
Vaccines made using SCV are grown in our proprietary Chinese Hamster Ovary (CHO) cells, an industry standard cell line for large scale bio-manufacturing with high yield and consistent batch quality.
Extensive advanced preclinical studies have shown that vaccines made using SCV platform are safe and efficacious after a single vaccination, eliciting potent T and B-cell immunity, and long lasting and protective vaccine immune responses. We are now focussed on final GLP toxicology and immunogencity studies in preparation for first in-human Phase I clinical trials.
Chief Scientific Officer
Chief Executive Officer
Sementis conducts it’s research and development activities in partnership with a team of experts in translational and clinical research, under the direction of Professor John Hayball who leads the Experimental Therapeutics Laboratory within the Clinical and Health Sciences Unit at the University of South Australia. The laboratories and team are located within the new state-of-the-art UniSA Cancer Research Institute within the Adelaide BioMed City precinct.
Liang is a qualified biological and chemical engineer, and gene technology molecular biologist. Liang is the lead researcher in vaccine design strategies. He obtained his PhD in Medical Science in 2012 at The University of Adelaide and leads the manufacturing process development program for our vaccines.
Tamara is a viral molecular biology specialist who obtained her PhD in 2009 at The University of Adelaide in collaboration with CSIRO. She is a lead researcher in the research and development team and coordinates our strategic partnerships with external stakeholders and collaborators.
Preethi is a trained clinician, immunologist and poxviral specialist having obtained her PhD at the Australian National University in 2016, investigating the mechanisms that drive the immune response to poxviruses. She uses these skills to contribute to novel design strategies to maximise the performance characteristics of our vaccine platform technology.
Natalie is a virologist and alphavirus specialist who obtained her PhD from the University of Western Australia in 2006. She has specialist expertise in viral pathogenesis (to BSL3 standards) in advanced preclinical infectious disease modelling and uses these skills to drive our infectious diseases programs.
Kerri is an experienced immunologist with many years of experience in preclinical and clinical immunotherapy development programs in oncology, reproductive immunology, allergy and infectious diseases. Kerri provides oversight and operational management to the Sementis’ R&D team and development program and projects.
Robyn is an experienced Research Associate proficient in Good Laboratory Practice (GLP) protocols and implementation. She provides essential support across the research and development team.
Gary is an experienced Research Associate with extensive skills in the implementation and monitoring of animal models of disease. He provides training, support, and reporting responsibilities across all the research and development programs.
Company Secretary and Chief Financial Officer
Non – Executive Director
Regulatory Affairs Consultant
Clinical Development Consultant